Research & Literature

Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.

Calvaruso G, Vitrano A, Di Maggio R, et al.

American journal of hematology 2015; (90(7)):634-8 doi:10.1002/ajh.24024.

Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatment.

Inati A, Noureldine MA, Mansour A, Abbas HA

BioMed research international 2015; (2015()):813098 doi:10.1155/2015/813098.

Does Profile of Hemoglobin Eβ-thalassemia Patients Change After Splenectomy? Experience of a Tertiary Thalassemia Care Centre in Eastern India.

Mandal PK, Ghosh MK, Bhattacharyya M

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2015; (31(4)):446-52 doi:10.1007/s12288-014-0498-6.

Increasing prevalence of thalassemia in America: Implications for primary care.

Sayani FA, Kwiatkowski JL

Annals of medicine 2015; (47(7)):592-604 doi:10.3109/07853890.2015.1091942.

Novel players in β-thalassemia dyserythropoiesis and new therapeutic strategies.

Arlet JB, Dussiot M, Moura IC, et al.

Current opinion in hematology 2016; (23(3)):181-8 doi:10.1097/MOH.0000000000000231.

Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.

Vitrano A, Calvaruso G, Tesé L, et al.

European journal of haematology 2016; (97(4)):361-70 doi:10.1111/ejh.12740.

Oxidative instability of hemoglobin E (β26 Glu→Lys) is increased in the presence of free α subunits and reversed by α-hemoglobin stabilizing protein (AHSP): Relevance to HbE/β-thalassemia.

Strader MB, Kassa T, Meng F, et al.

Redox biology 2016; (8()):363-74.

Modifying effect of XmnI, BCL11A, and HBS1L-MYB on clinical appearances: A study on β-thalassemia and hemoglobin E/β-thalassemia patients in Indonesia.

Rujito L, Basalamah M, Siswandari W, et al.

Hematology/oncology and stem cell therapy 2016; (9(2)):55-63.

Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors.

Tantiworawit A, Charoenkwan P, Hantrakool S, et al.

International journal of hematology 2016; (103(6)):643-8 doi:10.1007/s12185-016-1991-5.

Cortical bone invasion in non-transfusion-dependent thalassemia: tumefactive extramedullary hematopoiesis reviewed.

Masrouha KZ, Wazen J, Haddad A, et al.

La Radiologia medica 2016; (121(8)):626-34 doi:10.1007/s11547-016-0638-1.

Laboratory diagnosis of thalassemia.

Brancaleoni V, Di Pierro E, Motta I, Cappellini MD

International journal of laboratory hematology 2016; (38 Suppl 1()):32-40 doi:10.1111/ijlh.12527.

Morbidities in non-transfusion-dependent thalassemia.

Saliba AN, Taher AT

Annals of the New York Academy of Sciences 2016; (1368(1)):82-94 doi:10.1111/nyas.13083.

Hemoglobin E Hemoglobinopathy in an Adult from Assam with Unusual Presentation: A Diagnostic Dilemma.

Kiran SS, Aithal S, Belagavi CS

Journal of laboratory physicians 2016; (8(2)):116-9 doi:10.4103/0974-2727.180793.

Molecular Understanding of Non-Transfusion-Dependent Thalassemia Associated with Hemoglobin E-β-Thalassemia in Northeast Thailand.

Yamsri S, Pakdee N, Fucharoen G, et al.

Acta haematologica 2016; (136(4)):233-239 doi:10.1159/000449120.

β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint.

De Sanctis V, Kattamis C, Canatan D, et al.

Mediterranean journal of hematology and infectious diseases 2017; (9(1)):e2017018 doi:10.4084/MJHID.2017.018.

Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST).

Vichinsky E, El-Beshlawy A, Al Zoebie A, et al.

Pediatric blood & cancer 2017; (64(9)) doi:10.1002/pbc.26507.

Incomplete paraplegia caused by extramedullary hematopoiesis in a patient with thalassemia intermedia.

Hisamud-Din N, Mustafah NM, Fauzi AA, Hashim NM

Spinal cord series and cases 2017; (3()):17020 doi:10.1038/scsandc.2017.20.

Whole-exome sequencing identifies an α-globin cluster triplication resulting in increased clinical severity of β-thalassemia.

Steinberg-Shemer O, Ulirsch JC, Noy-Lotan S, et al.

Cold Spring Harbor molecular case studies 2017; (3(6)) doi:10.1101/mcs.a001941.

Epidemiologic study of major complications in adolescent and adult patients with thalassemia in Northeastern Thailand: the E-SAAN study phase I.

Teawtrakul N, Jetsrisuparb A, Pongudom S, et al.

Hematology (Amsterdam, Netherlands) 2018; (23(1)):55-60 doi:10.1080/10245332.2017.1358845.

Hydroxyurea for hemoglobin E/β-thalassemia: a systematic review and meta-analysis.

Algiraigri AH, Kassam A

International journal of hematology 2017; (106(6)):748-756 doi:10.1007/s12185-017-2307-0.

Prevalence of low bone mass among adolescents with nontransfusion-dependent hemoglobin E/β-thalassemia and its relationship with anemia severity.

Nakavachara P, Petchkul J, Jeerawongpanich K, et al.

Pediatric blood & cancer 2018; (65(1)) doi:10.1002/pbc.26744.

Iron overload in thalassemia: different organs at different rates.

Taher AT, Saliba AN

Hematology. American Society of Hematology. Education Program 2017; (2017(1)):265-271 doi:10.1182/asheducation-2017.1.265.

New therapeutic targets in transfusion-dependent and -independent thalassemia.

Cappellini MD, Motta I

Hematology. American Society of Hematology. Education Program 2017; (2017(1)):278-283 doi:10.1182/asheducation-2017.1.278.

Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.

Sleiman J, Tarhini A, Bou-Fakhredin R, et al.

International journal of molecular sciences 2018; (19(1)) doi:10.3390/ijms19010182.

A prospective analysis for prevalence of complications in Thai nontransfusion-dependent Hb E/β-thalassemia and α-thalassemia (Hb H disease).

Ekwattanakit S, Siritanaratkul N, Viprakasit V

American journal of hematology 2018; (93(5)):623-629 doi:10.1002/ajh.25046.

Clinical Classification, Screening and Diagnosis for Thalassemia.

Viprakasit V, Ekwattanakit S

Hematology/oncology clinics of North America 2018; (32(2)):193-211 doi:10.1016/j.hoc.2017.11.006.

The Correlation of Cardiac and Hepatic Hemosiderosis as Measured by T2*MRI Technique with Ferritin Levels and Hemochromatosis Gene Mutations in Iranian Patients with Beta Thalassemia Major.

Soltanpour MS, Davari K

Oman medical journal 2018; (33(1)):48-54 doi:10.5001/omj.2018.09.

Engineered U7 snRNA mediates sustained splicing correction in erythroid cells from β-thalassemia/HbE patients.

Preedagasamzin S, Nualkaew T, Pongrujikorn T, et al.

Biochemical and biophysical research communications 2018; (499(1)):86-92 doi:10.1016/j.bbrc.2018.03.102.

Late effects after hematopoietic stem cell transplantation for β-thalassemia major: the French national experience.

Rahal I, Galambrun C, Bertrand Y, et al.

Haematologica 2018; (103(7)):1143-1149 doi:10.3324/haematol.2017.183467.

PREVALENCE AND RISK FACTORS FOR CARDIAC IRON OVERLOAD AND CARDIOVASCULAR COMPLICATIONS AMONG PATIENTS WITH THALASSEMIA IN NORTHERN THAILAND.

Tantiworawit A, Tapanya S, Phrommintikul A, et al.

The Southeast Asian journal of tropical medicine and public health 2016; (47(6)):1335-42.

The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.

Ballas SK, Zeidan AM, Duong VH, et al.

American journal of hematology 2018; (93(7)):943-952 doi:10.1002/ajh.25103.

Genotype-phenotype correlation among beta-thalassemia and beta-thalassemia/HbE disease in Thai children: predictable clinical spectrum using genotypic analysis.

Traivaree C, Monsereenusorn C, Rujkijyanont P, et al.

Journal of blood medicine 2018; (9()):35-41 doi:10.2147/JBM.S159295.

Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline.

Compernolle V, Chou ST, Tanael S, et al.

Transfusion 2018; (58(6)):1555-1566 doi:10.1111/trf.14611.

Transfusion practices and complications in thalassemia.

Lal A, Wong TE, Andrews J, et al.

Transfusion 2018; (58(12)):2826-2835 doi:10.1111/trf.14875.

Severe Liver Iron Concentrations (LIC) in 24 Patients with β-Thalassemia Major: Correlations with Serum Ferritin, Liver Enzymes and Endocrine Complications.

Kanbour I, Chandra P, Soliman A, et al.

Mediterranean journal of hematology and infectious diseases 2018; (10(1)):e2018062 doi:10.4084/MJHID.2018.062.

Jadenu® Substituting Exjade® in Iron Overloaded β-Thalassemia Major (BTM) Patients: A Preliminary Report of the Effects on the Tolerability, Serum Ferritin Level, Liver Iron Concentration and Biochemical Profiles.

Yassin MA, Soliman AT, De Sanctis V, et al.

Mediterranean journal of hematology and infectious diseases 2018; (10(1)):e2018064 doi:10.4084/MJHID.2018.064.

Vascular and hemostatic alterations associated with pulmonary hypertension in β-thalassemia hemoglobin E patients receiving regular transfusion and iron chelation.

Uaprasert N, Satitthummanid S, Akkawat B, et al.

Thrombosis research 2019; (174()):104-112 doi:10.1016/j.thromres.2018.12.021.

Red blood cell alloimmunisation in transfusion-dependent thalassaemia: a systematic review.

Franchini M, Forni GL, Marano G, et al.

Blood transfusion = Trasfusione del sangue 2019; (17(1)):4-15 doi:10.2450/2019.0229-18.

Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen.

Sun L, Wang N, Chen Y, et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019; (25(8)):1592-1596 doi:10.1016/j.bbmt.2019.03.028.

Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients: a historical cohort study in Southern Iran.

Bordbar M, Bozorgi H, Saki F, et al.

Journal of endocrinological investigation 2019; (42(12)):1467-1476 doi:10.1007/s40618-019-01072-z.

Mahidol Scoring for Assessing Various Grades of β Thalassemia Intermedia.

Mannan J, Naveed M, Ahdi SG

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2019; (29(7)):635-638 doi:10.29271/jcpsp.2019.07.635.

Challenges of blood transfusions in β-thalassemia.

Shah FT, Sayani F, Trompeter S, et al.

Blood reviews 2019; (37()):100588 doi:10.1016/j.blre.2019.100588.

Clinico-hematological Profile of Hb E-β Thalassemia-Prospective Analysis in a tertiary Care Centre.

Pani K, Sharma S, Murari M, et al.

The Journal of the Association of Physicians of India 2018; (66(6)):42-45.

Effective method of evaluating myocardial iron concentration in pediatric patients with thalassemia major.

Khaled A, Ezzat DA, Salem HA, et al.

Journal of blood medicine 2019; (10()):227-233 doi:10.2147/JBM.S204848.

The Effect of Blood Transfusion on Growth of Patients with Hb E/β-Thalassemia.

Chuansumrit A, Sirachainan N, Kitpoka P, et al.

Hemoglobin 2019; (43(4-5)):264-272 doi:10.1080/03630269.2019.1692863.

Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-dependent β-Thalassemia.

Betts M, Flight PA, Paramore LC, et al.

Clinical therapeutics 2020; (42(2)):322-337.e2 doi:10.1016/j.clinthera.2019.12.003.

Genetic polymorphisms of HbE/beta thalassemia related to clinical presentation: implications for clinical diversity.

Azman NF, Abdullah WZ, Hanafi S, et al.

Annals of hematology 2020; (99(4)):729-735 doi:10.1007/s00277-020-03927-5.

Key Determinants of Phenotypic Heterogeneity of Hb E/β Thalassemia: A Comparative Study from Eastern India.

Kalantri SA, Ray R, Choudhuri S, et al.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2020; (36(1)):123-128 doi:10.1007/s12288-019-01176-9.

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.

Cappellini MD, Viprakasit V, Taher AT, et al.

The New England journal of medicine 2020; (382(13)):1219-1231 doi:10.1056/NEJMoa1910182.

An assessment of the continuing medical education needs of US physicians in the management of patients with beta thalassemia.

Stacy S, Sheth S, Coleman B, Cerenzia W

Annals of hematology 2021; (100(1)):27-35 doi:10.1007/s00277-020-04246-5.

A Rare Case of Hemoglobin E/Beta-Thalassemia and Systemic Lupus Erythematosus.

Khamees I, Mohammad Obeidat I, Rozi W, Yassin MA

Cureus 2020; (12(9)):e10332 doi:10.7759/cureus.10332.

Challenges in chronic transfusion for patients with thalassemia.

Lal A

Hematology. American Society of Hematology. Education Program 2020; (2020(1)):160-166 doi:10.1182/hematology.2020000102.

The Prevalence of HBB Mutations among the Transfusion-Dependent and Non Transfusion-Dependent Hb E/β-Thalassemia Children in a Tertiary Center of West Bengal, India.

Saha J, Panja A, Nayek K

Hemoglobin 2021; (45(3)):157-162 doi:10.1080/03630269.2021.1933023.

Novel Therapeutic Advances in β-Thalassemia.

Makis A, Voskaridou E, Papassotiriou I, Hatzimichael E

Biology 2021; (10(6)) doi:10.3390/biology10060546.

Prenatal Screening and Diagnosis of ß-Thalassemia in India: Is ARMS-PCR Enough?

Ghosh S, Chakrabarti S, Bhattacharyya M

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2021; (37(3)):448-452 doi:10.1007/s12288-020-01370-0.

Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the XmnI Polymorphism.

Ghosh D, Panja A, Saha D, et al.

Genetic testing and molecular biomarkers 2021; (25(8)):563-570 doi:10.1089/gtmb.2021.0031.

Alloimmunization in transfused patients with constitutional anemias in Norway.

Furuseth MT, Alme C, Garvik LJ, et al.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2021; (60(5)):103257 doi:10.1016/j.transci.2021.103257.

Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta-thalassemia in Taiwan: A real-world analysis.

Tang CH, Furnback W, Wang BCM, et al.

Transfusion 2021; (61(10)):2906-2917 doi:10.1111/trf.16636.

Transfer of Care for People with Severe Forms of Thalassemia: Learning from Past Experiences to Create a Transition Plan.

Morse LA, Sawh RN

Journal of pediatric nursing 2021; (61()):378-386 doi:10.1016/j.pedn.2021.08.007.

Reduced hepcidin expression enhances iron overload in patients with HbE/β-thalassemia: Α comparative cross-sectional study.

Saad HKM, Taib WRW, Ismail I, et al.

Experimental and therapeutic medicine 2021; (22(6)):1402 doi:10.3892/etm.2021.10838.

Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia.

Thuret I, Ruggeri A, Angelucci E, Chabannon C

Stem cells translational medicine 2022; (11(4)):407-414 doi:10.1093/stcltm/szac007.

Iron overload status in patients with non-transfusion-dependent thalassemia in China.

Huang Y, Yang G, Wang M, et al.

Therapeutic advances in hematology 2022; (13()):20406207221084639 doi:10.1177/20406207221084639.

2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia.

Farmakis D, Porter J, Taher A, et al.

HemaSphere 2022; (6(8)):e732 doi:10.1097/HS9.0000000000000732.

Ocular manifestations in patients with transfusion-dependent β-thalassemia.

Akritidou F, Praidou A, Papamitsou T, et al.

Hippokratia 2021; (25(2)):79-82.

Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.

Taher AT, Cappellini MD, Kattamis A, et al.

The Lancet. Haematology 2022; (9(10)):e733-e744 doi:10.1016/S2352-3026(22)00208-3.

Non-Transfusion-Dependent Thalassemia: A Panoramic Review.

Shash H

Medicina (Kaunas, Lithuania) 2022; (58(10)) doi:10.3390/medicina58101496.

Whole exome sequencing and rare variant association study to identify genetic modifiers, KLF1 mutations, and a novel double mutation in Thai patients with hemoglobin E/beta-thalassemia.

Hantaweepant C, Suktitipat B, Pithukpakorn M, et al.

Hematology (Amsterdam, Netherlands) 2023; (28(1)):2187155 doi:10.1080/16078454.2023.2187155.

Essential genetic modifiers and their measurable impact in a community-recruited population analysis for non-severe hemoglobin E/β-thalassemia prenatal genetic counseling.

Wong P, Chitsobhak T, Jittasathian S, et al.

Blood cells, molecules & diseases 2023; (103()):102765 doi:10.1016/j.bcmd.2023.102765.

Case report: A novel 10.8-kb deletion identified in the β-globin gene through the long-read sequencing technology in a Chinese family with abnormal hemoglobin testing results.

Shao M, Wan Y, Cao W, et al.

Frontiers in medicine 2023; (10()):1192279 doi:10.3389/fmed.2023.1192279.

Clinico-Hematological Profile and Management of Children With Non-Transfusion Dependent Thalassemia (NTDT) at a Pediatric Center in Northern India.

Parakh N, Khan A, Sharma S, Chandra J

Indian pediatrics 2023; (60(8)):644-647.

Characterization of pediatric transfusion-dependent thalassemia patients in a large academic center.

Zarrabian D, Hanna M

Journal of clinical laboratory analysis 2023; (37(17-18)):e24962 doi:10.1002/jcla.24962.

Spectrum of Adrenal Dysfunction in Hemoglobin E/Beta Thalassemia.

Singha A, Mukhopadhyay P, Ghosh S

The Journal of clinical endocrinology and metabolism 2024; (109(2)):e562-e568 doi:10.1210/clinem/dgad579.

Molecular understanding of unusual HbE-β+-thalassemia with Hb phenotype similar to HbE heterozygote: simple and rapid differentiation using HbE levels.

Jomoui W, Satthakarn S, Panyasai S

Annals of medicine 2023; (55(2)):2267054 doi:10.1080/07853890.2023.2267054.

Molecular Characterization of Haemoglobin E.

Ejaz S, Mustafa G, Khaliq S, Mohsin S

JPMA. The Journal of the Pakistan Medical Association 2023; (73(12)):2357-2362 doi:10.47391/JPMA.7138.

Red blood cell indices in different hemoglobinopathies: A cross-sectional study in Eastern India.

Nandi A, Talukdar M, Bhattacharya S, et al.

Indian journal of pathology & microbiology 2024; (67(1)):115-120 doi:10.4103/ijpm.ijpm_1071_21.

Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.

Locatelli F, Lang P, Wall D, et al.

The New England journal of medicine 2024; (390(18)):1663-1676 doi:10.1056/NEJMoa2309673.

Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.

Musallam KM, Barella S, Origa R, et al.

Blood cells, molecules & diseases 2024; (107()):102859 doi:10.1016/j.bcmd.2024.102859.

Alpha globin gene alterations modifying the phenotype of homozygous beta thalassaemia.

Shaw J, Patra A, Khatun A, et al.

EJHaem 2024; (5(3)):440-446 doi:10.1002/jha2.923.

Characterization and Clinical Assessment of a Peculiar Case of Hemolytic Anemia.

Castelgrande F, Viola G, Calabrese C, et al.

Journal of hematology 2024; (13(3)):108-115 doi:10.14740/jh1204.

Regulatory Assessment of Casgevy for the Treatment of Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-Occlusive Crises.

Kerwash E, Sajic M, Rantell KR, et al.

Current issues in molecular biology 2024; (46(8)):8209-8225 doi:10.3390/cimb46080485.

Luspatercept: a treatment for ineffective erythropoiesis in thalassemia.

Musallam KM, Taher AT

Hematology. American Society of Hematology. Education Program 2024; (2024(1)):419-425 doi:10.1182/hematology.2024000567.

Assessing the auditory effects of oral chelation therapy drug Deferasirox in individuals with β-thalassemia major.

Tiwana BS, Aggarwal A, Bhagat S, et al.

World journal of otorhinolaryngology - head and neck surgery 2024; (10(4)):309-314 doi:10.1002/wjo2.150.

[Monitoring and interventions of growth disorders and endocrine function in children with transfusion-dependent thalassemia].

Fan X, Huang YY

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2025; (27(4)):389-394 doi:10.7499/j.issn.1008-8830.2501080.

Risk Stratification-Based Therapy for Children with E-beta Thalassemia: A 20-Year Follow-Up Study.

Ganesan K, Duraisamy S, Nair A, et al.

Indian pediatrics 2025; (62(7)):506-510 doi:10.1007/s13312-025-00089-3.

Beyond the blood: A practical guide to thalassemia care in the emergency department.

Mufarrij A, Hodroj MH, Charbel N, et al.

Blood reviews 2025; (74()):101327 doi:10.1016/j.blre.2025.101327.

Efficacy and safety of luspatercept in non-transfusion-dependent β-thalassemia: long-term results from the BEYOND study.

Taher AT, Viprakasit V, Kattamis A, et al.

Blood advances 2025; (9(23)):6108-6119 doi:10.1182/bloodadvances.2025016554.

Gene Therapies for Hemoglobinopathies: Efficacy, Cell Collection & Transfusion Support.

Inam Z, Han H, Webb J, Delaney M

Transfusion medicine reviews 2025; (39(4)):150930 doi:10.1016/j.tmrv.2025.150930.

Molecular Genetics and Recent Management Strategies of HB E-β Thalassemia.

Dolai TK, Roy S, Panja A

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2026; (42(2)):344-356 doi:10.1007/s12288-025-02074-z.

Transition from Pediatric to Adult Care in Patients with Transfusion-Dependent Beta-Thalassemia in France: A National Study Concerning a Rare Disease.

Szepetowski S, Benoit A, Berbis J, et al.

Journal of clinical medicine 2026; (15(6)) doi:10.3390/jcm15062203.

Current therapeutic landscape of β-thalassemia: focus on gene therapy.

Cheng AN, Kwiatkowski JL

Therapeutic advances in rare disease 2026; (7()):26330040261433028 doi:10.1177/26330040261433028.

Best Practices for Thalassaemia Management: Recommendations by Indian Society of Haematology and Blood Transfusion.

Dolai TK, Jena RK, Roy S, et al.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2026; (42(3)):679-696 doi:10.1007/s12288-026-02390-y.

Detection of the Hb Hoshida (HBB: C. 130 G > C) Variant in the Indian Population.

Sen A, Dolai TK

Hemoglobin 2026; (50(3)):264-270 doi:10.1080/03630269.2026.2671886.

Prenatal Diagnosis of Compound Heterozygous Beta-Thalassemia: A Report of Two Cases.

Jha S, Jha S, Jha VC, et al.

Cureus 2026; (18(4)):e107581 doi:10.7759/cureus.107581.

Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease.

Frangoul H, de la Fuente J, Chopra Y, et al.

The New England journal of medicine 2026; (395(10)):947-958 doi:10.1056/NEJMoa2603387.

Delayed recognition and significant morbidity in adults with non-transfusion-dependent thalassemia.

Cheng AN, Peslak S, Sheth S, et al.

Blood advances 2026; (10(18)):6051-6059 doi:10.1182/bloodadvances.2026020059.

Three-Dimensional Craniofacial Characteristics in Transfusion-Dependent and Non-Transfusion-Dependent Thalassemia Patients.

Tekeli D, Ozturk Z, Özsoy U, et al.

Journal of pediatric hematology/oncology 2026; (48(6)):e232-e240 doi:10.1097/MPH.0000000000003237.

Alternative conditioning regimens for hemoglobinopathy gene therapy: balancing efficacy, toxicity, and the next frontier.

Sharma A, Corbacioglu S

Blood advances 2026; (10(18)):6118-6123 doi:10.1182/bloodadvances.2026019856.

Genetic Mutations and Clinical Severity in Hemoglobin E/Beta-Thalassemia Patients in Bangladesh.

Mahzabin N, Islam IA, Dey M, et al.

Cureus 2026; (18(6)):e111264 doi:10.7759/cureus.111264.

Diagnosis and Management of Transfusion-Dependent Thalassemia: Evidence-Based Guidelines From the Pediatric Hematology Oncology Chapter of the Indian Academy of Pediatrics.

Radhakrishnan N, Dewan P, Chandra J, et al.

Indian pediatrics 2026; (63(9)):612-637 doi:10.1007/s13312-026-00366-9.

Precision Medicine in Transfusion-Dependent and Non-Transfusion-Dependent β-Thalassemia: Toward Personalized Diagnosis and Therapy.

Karen AA, Tluli O, Hashem IE, et al.

Hemoglobin 2026; (50(5)):405-413 doi:10.1080/03630269.2026.2709700.

2026 Update on Clinical Trials in β-Thalassemia.

Musallam KM, Locatelli F, Algeri M, et al.

American journal of hematology 2026; doi:10.1002/ajh.70472.

Translating CRISPR to Practice in the Clinic: Transformative Therapy in Hemoglobinopathies and Emerging Applications in Malignancies.

Salim Hammoud M, Hanna R

JCO oncology practice 2026; OP2600479 doi:10.1200/OP-26-00479.

Hemoglobin E Associated with Hemoglobin Constant Spring: Diagnostic Challenges in Heterozygous and Homozygous States.

Ropero P, Escribano S, Abío M, et al.

Hemoglobin 2026; 1-7 doi:10.1080/03630269.2026.2723419.

Evaluation of a Customized RDB-FTH Panel for β-Globin Variants in a Malaysian Tertiary Center.

Jalil N, Azma RZ, Alaudin H, et al.

Hemoglobin 2026; 1-9 doi:10.1080/03630269.2026.2732039.